MedTrace Logo

A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults

NCT07663032 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2026-07-28

No results posted yet for this study

Summary

The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa. The purpose of the current Phase 1 study is to evaluate the safety, reactogenicity, and the immune response induced by the Pan-Salmonella vaccine.

Conditions

Interventions

BIOLOGICAL

Pan-Salmonella-without-Alum (Low dose) vaccine

Participants receive low dose of the Pan-Salmonella-without-Alum.

BIOLOGICAL

Pan-Salmonella-without-Alum (Full dose) vaccine

Participants receive full dose of the Pan-Salmonella-without-Alum.

BIOLOGICAL

Typhoid Vi conjugate vaccine

Participants receive Typhoid Vi conjugate vaccine as control

OTHER

Placebo

Participants receive Placebo (saline solution) as control.

BIOLOGICAL

Pan-Salmonella-with-Alum (Low dose) vaccine

Participants receive low dose of the Pan-Salmonella-with-Alum.

BIOLOGICAL

Pan-Salmonella-with-Alum (Full dose) vaccine

Participants receive full dose of the Pan-Salmonella-with-Alum.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-24
Primary Completion
2027-11-14
Completion
2027-11-14

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07663032 on ClinicalTrials.gov